Key result
Achieving no evidence of disease through radical or semi-radical treatment was significantly associated with improved disease-specific survival in metastatic myxoid liposarcoma (HR 0.36; 95% CI 0.13-0.95).
Why the study?
Prognostic factors at the initial diagnosis of myxoid liposarcoma were known, but those at the diagnosis of metastasis remained unclear.
What are the prognostic factors for disease-specific survival in patients with metastatic myxoid liposarcoma?
Observational (n=48)
Yes
What are the prognostic factors for disease-specific survival in patients with metastatic myxoid liposarcoma?
Hazard Ratio: 0.36 (95% CI 0.13–0.95)
Achieving no evidence of disease with surgical resection or radiation therapy is associated with longer survival in metastatic myxoid liposarcoma patients.
NED achievement may inform prognosis in metastatic myxoid liposarcoma; leaves open whether local therapy improves outcomes in prospective studies.
Background Myxoid liposarcoma (MLS) has the tendency to metastasize extrapulmonary. Although prognostic factors at the initial diagnosis of MLS have been reported, those at diagnosis of metastasis remain unclear. The purpose of this study was to investigate the prognostic factors for disease-specific survival at the initial diagnosis of metastasis. Methods This retrospective observational study was conducted at three cancer centers and two university hospitals in Japan. Of 274 MLS patients pathologically diagnosed between 2001 and 2015, 48 metastatic patients were examined. Results Lung metastases were detected in nine patients (18.8%) and extrapulmonary metastases in 45 (93.8%). Interval from primary diagnosis to the first metastasis was significantly shorter in patients with lung metastases than without ( p = 0.007). Median disease-specific survival after diagnosis of metastases was 52.5 months in all patients. In multivariable analysis, liver metastasis (hazard ratio (HR), 2.71 [95% confidence interval (CI), 1.00–7.09]) and no evidence of disease (NED) achieved by radical treatment (resection with or without radiation therapy, or radiation therapy ≥60 Gy) or semi-radical (radiation therapy ≥40 Gy) treatment were significantly related to survival (HR, 0.36; 95%CI [0.13–0.95]). The number of metastases (odds ratio (OR), 0.44; 95%CI [0.25–0.78]) and abdominal/retroperitoneal metastases (OR, 0.09; 95%CI [0.008–0.95]) were the significant inhibitory factors of achieving NED. Conclusions This is the first study to statistically demonstrate the importance of achieving NED with surgical resection or radiation therapy for longer survival in metastatic MLS patients. As number of metastases was a significant factor for achieving NED, early detection of metastases might be important.
No takes yet. Share an insight, caveat, or question.
Shinoda et al. (2020) conducted an observational in Metastatic myxoid liposarcoma (n=48). Achieving no evidence of disease (NED) by radical or semi-radical treatment vs. Not achieving NED was evaluated on Disease-specific survival (HR 0.36, 95% CI 0.13-0.95). Achieving no evidence of disease through radical or semi-radical treatment was significantly associated with improved disease-specific survival in metastatic myxoid liposarcoma (HR 0.36; 95% CI 0.13-0.95).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: